SCHEMBL33530596

SCHEMBL33530596

O=CNCCc1ccccc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.58
GPR52 Q9Y2T5 1/20 0.41
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH7 P40394 1/20 0.39
IDO1 P14902 2/20 0.38
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
MPO P05164 1/20 0.35
KMT2A Q03164 1/20 0.35
RIPK1 Q13546 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
NLRP3 Q96P20 1/20 0.34
PLCG1 P19174 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5604774 1.00 TAAR1 (0.58) TAAR1GPR52ADH1BADH1CADH1A
SCHEMBL8763407 0.86 ADH1B (0.46) TAAR1ADH1BADH1CADH1AADH7
SCHEMBL25219502 0.82 TAAR1 (0.43) TAAR1ADH1BADH1CADH1AADH7
SCHEMBL30481241 0.82 TAAR1 (0.43) TAAR1ADH1BADH1CADH1AADH7
SCHEMBL5542317 0.80 ADH1B (0.52) TAAR1ADH1BADH1CADH1AADH7
SCHEMBL8763265 0.80 ADH1B (0.42) TAAR1ADH1BADH1CADH1AADH7
SCHEMBL1613352 0.78 TAAR1 (0.54) TAAR1GPR52IDO1TSHRKMT2A
SCHEMBL11780857 0.78 TAAR1 (0.41) TAAR1GPR52ADH1BADH1CADH1A
SCHEMBL5072950 0.77 MPO (0.61) TAAR1TSHRCA12CA2CA9
SCHEMBL10433878 0.77 ADH1B (0.46) TAAR1ADH1BADH1CADH1AADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 TAAR1 1518/4885GPR52 3796/4885ADH1B 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.